Int. J. Plant Bas. Pharm. (2022) 2(1), 111-117

INTERNATIONAL JOURNAL OF PLANT BASED PHARMACEUTICALS

https://ijpbp.com

RESEARCH ARTICLE

OPEN ACCESS

Natural phenolic compounds from *Satureja* L. as inhibitors of COVID-19 protease (Mpro): Computational investigations

Faika Başoğlu-Ünal[a,*], Selin Tufan[b,*], Nur Tan[b]

[a] *European University of Lefke, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Lefke, Northern Cyprus, TR-10 Mersin, Turkey*
[b] *Istanbul University, Faculty of Pharmacy, Department of Pharmacognosy, Beyazıt, Istanbul, Turkey*

ARTICLE INFO

Article History:

Received: 30 December 2021
Revised: 31 January 2022
Accepted: 31 January 2022
Available online: 06 January 2022

Edited by: E.S. Istifli

Keywords:
Satureja L.
Phenolic compounds
COVID-19
Protease inhibitor (Mpro)

ABSTRACT

Coronavirus (SARS-CoV-2) causes a new type of severe acute respiratory syndrome that first appeared in Wuhan in December 2019; it is a very fast-spreading and deadly virus. Therefore, urgent discovery or development of "lead compounds" against this virus is crucial. Natural compounds have always served as a great source, especially the use of traditional medicinal plants, in modern drug discovery. This study aimed to investigate the SARS-CoV-2 protease inhibition potential of the phenolic compounds in the genus *Satureja* L. The affinities of the chosen natural products were understood using molecular docking simulation against the SARS-CoV-2 protease enzyme. The study proved that three different phenolic compounds namely 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7,8-dimethoxy-4H-chromen-4-one, 2-(3,4-dimethoxyphenyl)-5,6-dihydroxy-7,8-dimethoxy-4H-chromen-4-one, and 5,6-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7,8-dimethoxy-4H-chromen-4-one obtained from *Satureja* L. taxa were found as promising against SARS-CoV-2 main protease.

1. Introduction

Coronavirus, named after the crown-like spikes on their surface, is defined as a family of enveloped, single-stranded, and positive-stranded RNA viruses containing helical nucleocapsids (Coronaviridiae family, Nidovirales line). It has been known that they cause acute and chronic respiratory, enteric and central nervous system diseases both in animals and humans (Orhan and Deniz, 2020; Weiss and Navas-Martin, 2005). As of December 21, there are 275,839,211 COVID-19 cases, and 5,377,934 deaths from 219 different countries are confirmed, and the numbers, unfortunately, keep rising (WHO, 2020).

It is important to understand the virulence mechanisms of SARS-CoV-2 in order to design an effective drug molecule. Therefore, many studies are being carried out to understand the mechanisms; since the SARS-CoV-2 pandemic begins. As a result of the studies, several points exhibit which receptor/receptors are crucial for antiviral activity. Human ACE-2 can be recognized easier than the former virus by SARS-CoV-2; thus, the transmission capacity of human-to-human is expanding. On the other hand, the main protease determined as the PDB 6LU7 protein structure of SARS-CoV-2 is another significant receptor that plays a role in viral gene replication and expression (Rauf et al., 2021).

Concurrently, another property of the SARS-CoV-2 virus is that it possesses "genomic proofreading" in extremely few viruses. Thus, the virus doesn't become either weak or inactive by repairing the mutated RNA. That is why the old antiviral drugs used for different viruses, such as ribavirin, have no effect (Robson et al., 2020). All in all, novel drugs are required to treat the disease.

Mpro in CoV possesses a key role during viral proteolytic maturation; as a result, it might be useful as a marker or potential target protein needed to reduce infection spread by inhibiting the viral polyprotein cleavage (Wax and Christian, 2020). As a result, Mpro protease in COVID-19 serves as a potential drug target for the treatment of COVID-19 infection. But SARS-CoV-2 has mutated

* Corresponding author:
E-mail address: fabasoglu@eul.edu.tr (F. Başoğlu-Ünal)
Selin.tufan@istanbul.edu.tr (S. Tufan)
e-ISSN: 2791-7509
doi:

Please cite this article as: Başoğlu-Ünal, F., Tufan, S., Tan, N., 2022. Natural phenolic compounds from Satureja L. as inhibitors of COVID-19 protease (Mpro): Computational investigations. International Journal of Plant Based Pharmaceuticals, 2(1), 111-117.

many times; however, the main protease that plays a crucial role in viral gene expression and replication hasn't mutated yet. Therefore, the main protease, Mpro, is chosen to propose a probable natural anti-coronavirus product (Rajagopal et al., 2020; Rauf et al., 2021).



Figure 1. Natural phenolic compounds from *Satureja* L.

Under the given circumstances and urgent need to treat COVID-19 natural products, especially medicinal plants, have gone under investigation by different research groups (Bekut et al., 2018; Orhan and Deniz, 2020). The selection of medicinal plants is a deliberate process. Plant material itself or extracts obtained from medicinal plants have been safely used by various cultures worldwide for years (Barnes et al., 2007; Heinrich, 2000; Momtaz and Abdollahi, 2010; Mukhtar et al., 2008). The efficacy, availability, and affordability of medicinal plants have always been the key point in folk medicine. Also, the use of these medicinal plants for years eliminates most of the question marks against their safety as well as their use as food (Barnes et al., 2007). Along with direct use of plant material or

extracts, approximately 25% of the synthetic active compounds in current treatment are derived from natural compounds (Momtaz and Abdollahi, 2010).

Lamiaceae is one of the most important and large plant families, which is widespread. Due to their chemical constituent profile is widely used in both pharmaceutical and food industries (Bekut et al., 2018; Raja, 2012). Moreover, taxa in the Lamiaceae family have drawn attention due to their antiretroviral properties (Abad et al., 1999; Bekut et al., 2018). Newly published studies exhibited that the extracts from Lamiaceae such as *Mentha piperita*, *Mosla* sp., *Ocimum kilim,* and *scharicum* possessed antiviral effects against coronavirus. Additionally, the extracts were reported to have high inhibitory activities on ACE2 receptors and COVID Mpro (Jalali et al., 2021).

The genus *Satureja* L. belongs to the Lamiaceae and contains terpenoids and phenolic compounds as major compounds (Davis, 1982; Tepe and Cilkiz, 2016). Especially infusions and decoctions, which are rich in phenolic compounds, prepared from the *Satureja* L. taxa, have traditionally been used against cold, flu, wound antiseptic, cough in Turkey (Chorianopoulos et al., 2006; Emre et al., 2020; Giweli et al., 2012; Güllüce et al., 2003; Ilhan et al., 2020; Ozcelik et al., 2011), a muscle pain reliever, tonic, and carminative in the treatment of stomach and intestinal ailments such as cramps, nausea, indigestion, and diarrhea (Zargari, 1990). Along with ethnobotanical uses, researches revealed that *Satureja* L. taxa have antimicrobial, antioxidant, antiviral, anti-diabetes, anti-hyperlipidemic, reproductive stimulating, expectorant, and vasodilator activities (Abdollahi et al., 2003; Amanlou et al., 2005; Momtaz and Abdollahi, 2010; Sahin et al., 2003; Tepe and Cilkiz, 2016; Vosough-Ghanbari et al., 2010).

Table 1. Natural phenolic compounds docking results based on binding energy calculations and their ADMET properties

Compound name	Docking score[a]	MW[b]	QlogPo/w[c]	Human oral absorption %[d]	PSA[e]	HBD[f]	HBA[g]	Lipinski rule of five
NativeLigand (RZS)	-5.421	147.18	1.872	93	48.57	1	3	0
1	-7.190	360.32	2.004	79	117.30	2	6	0
2	-7.182	374.35	2.715	92	103.50	1	6	0
3	-6.903	360.32	1.994	79	117.30	2	6	0
4	-6.803	272.26	1.603	74	99.25	2	4	0
5	-7.018	346.34	2.594	91	95.27	1	5.5	0
6	-6.889	284.27	2.384	87	84.81	1	3.75	0
7	-6.573	314.29	2.593	90	91.05	1	4.5	0
8	-6.533	344.32	2.655	91	98.81	1	5.25	0
9	-6.690	330.29	1.815	76	113.16	2	5.25	0
10	-7.804	354.31	-0.298	18	180.43	6	9.65	0
11	-6.870	170.12	-0.586	41	115.35	4	4.25	0
12	-6.570	372.33	1.392	40	165.92	5	7	0
13	-5.599	168.15	1.005	66	80.25	2	3.5	0
14	-4.915	154.12	0.014	53	93.92	3	3.5	0
15	-5.208	332.44	3.543	89	67.22	3	3.5	0
16	-4.872	194.19	1.268	66	82.41	2	3.5	0
17	-4.968	180.13	0.519	54	96.08	3	3.5	0
18	-8.841	164.16	1.403	67	74.65	2	2.75	0

[a]Docking score (kcal/mol).
[b]Molecular weight (g/mol) (recommended value ≤ 500)
[c]Logarithm of the octanol/water ratio coefficient of compound (recommended value < 5).
[d]Percentage oral absorption (< 25% weak and > 85% strong).
[e]Polar surface area (Å) (recommended value ≤ 140 Å).
[f]Hydrogen bond donar (recommended value ≤ 5)
[g]Hydrogen bond acceptor (recommended value ≤ 10)

Initially, it is necessary to evaluate the probable inhibitory effects of natural compounds by screening. For this reason, keeping in view the pharmacological activities based on previous literature, 18 natural compounds from *Satureja* L. were selected. ADMET property calculations were also estimated for all selected compounds, and the interactions with the active site (PDB ID: 5R82) were visualized.

In light of the information provided above, phenolic compounds of *Satureja* L. are a great "starting point" in discovering and developing lead compounds against COVID-19. In this research, molecular docking studies were performed on 18 phenolic compounds (Figure 1).

2. Materials and methods

2.1. Data set

Chlorogenic acid (1) (Silva et al., 2009; Tepe and Cilkiz, 2016), 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7,8-dimethoxy-4H-chromen-4-one (2) (Moghaddam et al., 2007), 2-(3,4-dimethoxyphenyl)-5,6-dihydroxy-7,8-dimethoxy-4H-chromen-4-one (3) (Gohari et al., 2009), 5,6-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7,8-dimethoxy-4H-chromen-4-one (4) (Gohari et al., 2009), gallic acid (5) (Cetojevic-Simin et al., 2004), apigenin (6) (Cetojevic-Simin et al., 2004), xanthomicrol (7) (Malmir et al., 2012), genkwanin (8) (Skoula et al., 2005), cirsimaritin (9) (Skoula et al., 2005), rosmarinic acid (10) (Cetojevic-Simin et al., 2008), cirsilineol (11) (Skoula et al., 2005), 6-hydroxyluteolin-7,3i-dimethyl ether (12) (Skoula et al., 2005), vanillic acid (13) (Palavra et al., 2011), protocatechuic acid (14) (Palavra et al., 2011), carnosic acid (15) (Kosar, 2003), ferulic acid (16) (Askun et al., 2013; Cetojevic-Simin et al., 2012), caffeic acid (17) (Cetojevic-Simin et al., 2012), and *p*-coumaric acid (18) (Askun et al., 2013; Cetojevic-Simin et al., 2012) were identified previously in *Satureja* L. taxa.

2.2. Molecular docking

The molecular docking studies of 18 phenolic compounds on COVID-19 Mpro (Hall Jr and Ji, 2020) were examined using the Schrödinger program. COVID-19 protease crystal structure was retrieved from protein data bank (PDB ID: 5R82: Resolution 1.31 Å) (Rajagopal et al., 2020; Wax and Christian, 2020). The docking calculations were carried out using the Glide SP (standard precision) module of the Schrödinger Suite (Friesner et al., 2004, 2006; Halgren et al., 2004). The RMSD value between the docked pose and the crystal

conformation of the native ligand (6-(ethylamino)pyridine-3-carbonitrile) was found as 1.595 Å.

The ADMET properties of the selected compounds such as molecular weight, HBA, HBD, logPo/w were determined by the QikProp module (Ligprep and Macromodel, 2011) of the Schrodinger suite (Table 1).

3. Results and discussion

A docking study was performed on 18 phenolic compounds from *Satureja* L. against SARS-CoV-2 protease (Mpro). Tables 1 and 2 show the docking score and amino acid residues, which form various interactions with the chosen compounds, while Figure 2 shows 2-dimensional ligand-receptor interactions of probable more active compounds. Additionally, their 3-dimensional ligand-receptor interactions are displayed in Figure 3.

In this study, 18 phenolic compounds show hydrogen bond and π- π interaction with many amino acid residues in the active region but active/inactive ranking of the compounds cannot be done precisely based on the energy values obtained as a result of primitive scoring algorithms (Başoğlu et al., 2021). Despite that, pharmacologically active conformations of the ligands and the determination of their binding modes to the receptor can be done successfully. Therefore, the binding affinities of the chosen natural phenolic compounds were determined by analyzing binding conformations and interactions of each compound with the active site of the receptor.

Table 2. Receptor interaction with chosen phenolic compounds and RZS into the binding site in the COVID-19 main protease

Compound name	Receptor amino acids
NativeLigand (RZS)	Gln189, His41
1	Thr26, Gln189, Gly143
2	Thr26, Gly143, His41
3	Thr26, Gly143, His164, His41
4	Phe140, Glu166, Arg188
5	Glu166, Gly143, Cys44
6	Thr190
7	Arg188
8	Thr26, Gly143, Glu189
9	Thr26, Gly143, Glu189
10	Gly143, Thr190
11	Gly143, His41
12	Phe140, Glu166
13	Gly143, Glu166
14	His41, Gly143
15	Glu166
16	Gly143, Gln189, His41
17	Gly143, Gln189, His41
18	His41



Figure 2. 2D representation of docking of compounds: compound 1 (a), compound 2 (b), compound 3 (c) into the binding site of the COVID-19 main protease

Considering the previous *in silico* studies reported in the literature, it is obvious that some amino acid residues such as Gln19, Thr24, Thr25, Thr26, Leu27, His41, Ser46, Met49, Asn119, Asn142, Gly143, His164, Met165, Glu166, Asp187, Arg188, and Gln189, might play a strong role in the inhibitory activity (Rajagopal et al., 2021; Thirumalaisamy et al., 2021).

Compounds 1, 2, 3, 8, and 9 looks similar with minor differences. Considering these differences and their binding poses, -OH at 4th position on phenyl is required for H-bond with Gln189, a critical amino acid residue. The significant H-bond with Gln189 is formed with -OH at the 4th position of the phenyl of compounds 16 and 17.



Figure 3. 3D representation of docking of compounds: compound 1 (a), compound 2 (b), compound 3 (c) into the binding site of the COVID-19 main protease
(The yellow dash bond indicates H-bond, the blue dash bond illustrates pi-pi interaction.)

Compounds 1, 2, 3, 8, and 9 generate H-bond with Thr26, which is also among one of the crucial amino acid residues against SARS-CoV-2. Flavonoids could be a significant moiety for H-bond generation since these carry hydroxy moiety at either 5th or 6th position. However, compounds 6 and 7 have an H-bond with different amino acid residues, Thr190 and Arg188, respectively. Interestingly, their structures are similar to compounds 1, 2, 3, 8, and 9. Carbonyl group and 5th position -OH of flavonoid are located at 5Å distance from the Gln189, Thr26 amino acid residue due to their positions within the receptor active site. Therefore, no H-bond is formed with these amino acids, which are predicted to be important for activity. The same state is true for compound 18. The only amino acid residue that can form H-bond with -OH at the 4th position of phenyl is His41; therefore, it's important for its activity.

Additionally, an extra pi-pi interaction is observed between compounds 2, 4, 11, 16, 17, and 18's aromatic ring and His41 amino acid residue.

Compounds 1, 2, and 3 generated more hydrophobic interactions with amino acid residues, significant for the inhibition effectiveness. As seen clearly in Figure 3, compound 1 showed hydrophobic interaction with Thr26, compound 2 exhibited hydrophobic interaction with Thr26 and His41, and compound 3 generated 3 hydrophobic interactions with different amino acids residues Arg188, Gle189, and His49. That might be why the docking scores of compounds 1, 2, and 3 are higher than the other chosen phenolic compounds.

Furthermore, chemo-informatic properties were calculated using the QikProp module in Maestro Schrödinger. The compounds' permeability and solubility must be estimated using these evaluations, especially for novel drug discovery, which will be administrated orally. Lipinski's rule of 5 foretells whether compounds have good absorption and permeation. Regarding the rule of 5, for good absorption and permeation properties, the number of hydrogen bond donors, acceptors, molecular weight, and

octanol/water coefficients should be within certain limits (Lipinski et al., 1997). The selected 18 phenolic compounds from *Satureja* L. showed acceptable values and obeyed the rule of 5 (Table 1). By considering their logPo/w values, it might be possible that the affinity for the target of protease increased when logPo/w approached two.

Moreover, PSA is another parameter used for the drug's optimization ability to permeate cells. Preferably, from the previous research point, the PSA value should be less than 90 (Başoğlu et al., 2021). But almost all the chosen 18 compounds except compounds 6, 13, 15, and 16 possess higher values than the standard.

4. Conclusions

Medicinal plants have always had an important role in modern drug discovery and may also be a pioneer for COVID-19 treatment. As a result of this study, we recommended 3 different natural phenolic compounds found in *Satureja* L. taxa as promising against SARS-CoV-2 main protease inhibitors by evaluating their affinities against SARS-CoV-2 main protease and also ADMET properties. It is anticipated that compounds 1, 2, and 3 might be promising inhibitors of the main protease, and further *in vitro* studies can be conducted based on the preliminary *in silico* study carried out in this work.

Acknowledgments

The support of Rita Podzuna, who offered a free trial of Schrödinger from Schrödinger GmbH, is greatly appreciated. Additionally, we thank Dr. Abdulilah Ece from Biruni University for his valuable comments and support.

Conflict of interest

The authors confirm that there are no known conflicts of interest.

CRediT authorship contribution statement

Faika Başoğlu-Ünal: Resources, Conceptualization, Visualization, Formal analysis, Writing-original draft, Investigation, Methodology
Selin Tufan: Resources, Conceptualization, Data curation, Writing-original draft, Methodology
Nur Tan: Supervision

ORCID Numbers of the Authors

F. Başoğlu-Ünal: 0000-0002-4890-3124
S. Tufan: 0000-0002-9173-3423
N. Tan: 0000-0001-7958-1917

Supplementary File

None.

References

Abad, M.J., Bermejo, P., Gonzales, E., Iglesias, I., Irurzun, A., Carrasco, L., 1999. Antiviral activity of Bolivian plant extracts. *General Pharmacology: The Vascular System*, 32(4), 499-503.

Abdollahi, M., Salehnia, A., Mortazavi, S.H.R., Ebrahimi, M., Shafiee, A., Fouladian, F., Kazemi, A., 2003. Antioxidant, antidiabetic, anti-hyperlipidemic, reproduction stimulatory properties and safety of essential oil of *Satureja khuzestanica* in rat *in vivo*: a toxicopharmacological study. *Medical Science Monitor*, 9(9), BR331-BR335.

Amanlou, M., Dadkhah, F., Salehnia, A., Farsam, H., Dehpour, A.R., 2005. An anti-inflammatory and anti-nociceptive effects of hydroalcoholic extract of *Satureja khuzistanica* Jamzad extract. *Journal of Pharmaceutical Sciences*, 8(1), 102-106.

Askun, T., Tekwu, E.M., Satil, F., Modanlioglu, S., Aydeniz, H., 2013. Preliminary antimycobacterial study on selected Turkish plants (Lamiaceae) against *Mycobacterium tuberculosis* and search for some phenolic constituents. *BMC Complementary and Alternative Medicine*, 13(1), 1-11.

Barnes, J., Anderson, L.A., Phillipson, J.D., 2007. Herbal Medicines: a guide for healthcare professionals. London: Pharmaceutical Press.

Başoğlu, F., Ulusoy-Güzeldemirci, N., Akalın-Çiftçi, G., Çetinkaya, S., Ece, A., 2021. Novel imidazo [2, 1-b] thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: synthesis, *in silico*, and *in vitro* evaluation. *Chemical Biology & Drug Design*, 98(2), 270-282

Bekut, M., Brkić, S., Kladar, N., Dragović, G., Gavarić, N., Božin, B., 2018. Potential of selected Lamiaceae plants in anti (retro) viral therapy. *Pharmacological Research*, 133, 301-314.

Cetojevic-Simin, D.D., Bogdanovic, G.M., Cvetkovic, D.D., Velicanski, A.S., 2008. Antiproliferative and antimicrobial activity of traditional Kombucha and *Satureja montana* L. Kombucha. *Journal of BUON*, 13(3), 395-401.

Cetojevic-Simin, D.D., Canadanovic-Brunet, J.M., Bogdanovic, G.M., Cetkovic, G.S., Tumbas, V.T., Djilas, S.M., 2004. Antioxidative and antiproliferative effects of *Satureja montana* L. extracts. *Journal of BUON*, 9(4), 443-449.

Cetojevic-Simin, D.D., Velićanski, A.S., Cvetković, D.D., Markov, S.L., Mrđanović, J.Ž., Bogdanović, V.V., Šolajić, S.V., 2012. Bioactivity of lemon balm kombucha. *Food and Bioprocess Technology*, 5(5), 1756-1765.

Chorianopoulos, N., Evergetis, E., Mallouchos, A., Kalpoutzakis, E., Nychas, G.J., Haroutounian, S.A., 2006. Characterization of the essential oil volatiles of *Satureja thymbra* and *Satureja parnassica*: Influence of harvesting time and antimicrobial activity. *Journal of Agricultural and Food Chemistry*, 54(8), 3139-3145.

Davis, P.H., 1982. Flora of Turkey and The East Aegan Islands (Vol. 7). Edinburgh: Edinburgh University Press.

Emre, İ., Kurşat, M., Yilmaz, Ö., Erecevit, P., 2020. Chemical compositions, radical scavenging capacities and antimicrobial activities in seeds of *Satureja hortensis* L. and *Mentha spicata* L. subsp. *spicata* from Turkey. *Brazilian Journal of Biology*, 81, 144-153.

Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Shenkin, P.S., 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *Journal of Medicinal Chemistry*, 47(7), 1739-1749.

Friesner, R.A., Murphy, R.B., Repasky, M.P., Frye, L.L., Greenwood, J.R., Halgren, T.A., Mainz, D.T., 2006. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein− ligand complexes. *Journal of Medicinal Chemistry*, 49(21), 6177-6196.

Giweli, A., Džamić, A.M., Soković, M., Ristić, M.S., Marin, P.D., 2012. Antimicrobial and antioxidant activities of essential oils of *Satureja thymbra* growing wild in Libya. *Molecules*, 17(5), 4836-4850.

Gohari, A.R., Saeidnia, S., Gohari, M.R., Moradi-Afrapoli, F., Malmir, M., Hadjiakhoondi, A., 2009. Bioactive flavonoids from *Satureja atropatana* Bonge. *Natural Product Research*, 23(17), 1609-1614.

Güllüce, M., Sökmen, M., Daferera, D., Ağar, G., Özkan, H., Kartal, N., Şahin, F. (2003). *In vitro* antibacterial, antifungal, and antioxidant activities of the essential oil and methanol extracts of herbal parts and callus cultures of *Satureja hortensis* L. *Journal of Agricultural and Food Chemistry*, 51(14), 3958-3965.

Halgren, T.A., Murphy, R.B., Friesner, R.A., Beard, H.S., Frye, L.L., Pollard, W.T., Banks, J.L., 2004. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *Journal of Medicinal Chemistry*, 47(7), 1750-1759.

Hall Jr, D.C., Ji, H.F., 2020. A search for medications to treat COVID-19 via *in silico* molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. *Travel Medicine and Infectious Disease*, 35, 101646.

Heinrich, M., 2000. Ethnobotany and its role in drug development. *Phytotherapy Research*, 14(7), 479-488.

Ilhan, E., Cesur, S., Guler, E., Topal, F., Albayrak, D., Guncu, M.M., Gunduz, O., 2020. Development of *Satureja cuneifolia*-loaded sodium alginate/polyethylene glycol scaffolds produced by 3D-printing technology as a diabetic wound dressing material. International *Journal of Biological Macromolecules*, 161, 1040-1054.

Jalali, A., Dabaghian, F., Akbrialiabad, H., Foroughinia, F., Zarshenas, M.M., 2021. A pharmacology-based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID-19. *Phytotherapy Research*, 35(4), 1925-1938.

Kosar, M., Dorman, H.J.D., Bachmayer, O., Baser, K.H.C., Hiltunen, R., 2003. An improved on-line HPLC-DPPH method for the screening of free radical scavenging compounds in water extracts of Lamiaceae plants. *Chemistry of Natural Compounds*, 39(2), 161-166.

Ligprep, M., Macromodel, G., 2011. QikProp; Schrodinger, LLC; New York.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*, 23(1-3), 3-25.

Malmir, M., Gohari, A.R., Saeidnia, S., 2012. Flavonoids from the aerial parts of *Satureja khuzestanica*. *Planta Medica*, 78(11), PI365.

Moghaddam, F.M., Farimani, M.M., Salahvarzi, S., Amin, G., 2007. Chemical constituents of dichloromethane extract of cultivated *Satureja khuzistanica*. *Evidence-Based Complementary and Alternative Medicine*, 4(1), 95-98.

Momtaz, S., Abdollahi, M., 2010. An update on pharmacology of *Satureja* species; from antioxidant, antimicrobial, anti-diabetes and anti-hyperlipidemic to reproductive stimulation. *International Journal of Pharmacology*, 6(4), 454-461.

Mukhtar, M., Arshad, M., Ahmad, M., Pomerantz, R.J., Wigdahl, B., Parveen, Z., 2008. Antiviral potentials of medicinal plants. *Virus Research*, 131(2), 111-120.
Orhan, I.E., Deniz, F.S.S., 2020. Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS-CoV-2?. *Natural Products and Bioprospecting*, 10(4), 171-186.
Ozcelik, B., Kartal, M., Orhan, I., 2011. Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. *Pharmaceutical Biology*, 49(4), 396-402.
Palavra, A.M.F., Coelho, J.P., Barroso, J.G., Rauter, A.P., Fareleira, J.M.N.A., Mainar, A., ovais, J.M., 2011. Supercritical carbon dioxide extraction of bioactive compounds from microalgae and volatile oils from aromatic plants. *The Journal of Supercritical Fluids*, 60, 21-27.
Raja, R.R., 2012. Medicinally potential plants of Labiatae (Lamiaceae) family: an overview. *Research Journal of Medicinal Plant*, 6(3), 203-213.
Rajagopal, K., Varakumar, P., Aparna, B., Byran, G., Jupudi, S., 2021. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies. *Journal of Biomolecular Structure and Dynamics*, 39(15), 5551-5562.
Rajagopal, K., Varakumar, P., Baliwada, A., Byran, G., 2020. Activity of phytochemical constituents of *Curcuma longa* (turmeric) and *Andrographis paniculata* against coronavirus (COVID-19): an *in silico* approach. *Future Journal of Pharmaceutical Sciences*, 6(1), 1-10.
Rauf, A., Rashid, U., Khalil, A.A., Khan, S.A., Anwar, S., Alafnan, A., Rengasamy, K.R., 2021. Docking-based virtual screening and identification of potential COVID-19 main protease inhibitors from brown algae. *South African Journal of Botany*, 143, 428-434.
Robson, F., Khan, K.S., Le, T.K., Paris, C., Demirbag, S., Barfuss, P., Ng, W.L., 2020. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. *Molecular Cell*, 79(5), 710-727.
Sahin, F., Karaman, I., Güllüce, M., Öğütçü, H., Şengül, M., Adıgüzel, A., Kotan, R., 2003. Evaluation of antimicrobial activities of *Satureja hortensis* L. *Journal of Ethnopharmacology*, 87(1), 61-65.
Silva, F.V., Martins, A., Salta, J., Neng, N.R., Nogueira, J.M., Mira, D., Rauter, A.P., 2009. Phytochemical profile and anticholinesterase and antimicrobial activities of supercritical versus conventional extracts of *Satureja montana*. *Journal of Agricultural and Food Chemistry*, 57(24), 11557-11563.
Skoula, M., Grayer, R.J., Kite, G.C., 2005. Surface flavonoids in *Satureja thymbra* and *Satureja spinosa* (Lamiaceae). *Biochemical Systematics and Ecology*, 33(5), 541-544.
Tepe, B., Cilkiz, M., 2016. A pharmacological and phytochemical overview on *Satureja*. *Pharmaceutical Biology*, 54(3), 375-412.
Thirumalaisamy, R., Aroulmoji, V., Iqbal, M.N., Deepa, M., Sivasankar, C., Khan, R., Selvankumar, T., 2021. Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins. *Journal of Molecular Structure*, 1238, 130457.
Vosough-Ghanbari, S., Rahimi, R., Kharabaf, S., Zeinali, S., Mohammadirad, A., Amini, S., Abdollahi, M., 2010. Effects of *Satureja khuzestanica* on serum glucose, lipids and markers of oxidative stress in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. Evi*dence-Based Complementary and Alternative Medicine*, 7(4), 465-470.
Wax, R.S., Christian, M.D., 2020. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*, 67(5), 568-576.
Weiss, S.R., Navas-Martin, S., 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiology and Molecular Biology Reviews*, 69(4), 635-664.
WHO (World Health Organization), 2020. Coronavirus Disease (COVID-19) Dashboard. Retrieved from https://covid19.who.int/info.
Zargari, A., 1990. Medicinal Plants (Vol. 1). Tehran: Tehran University Press.

Reviewed by:

Emine ERDAG: Near East University, Nicosia, NORTHERN CYPRUS
Mustafa EMIRIK: Recep Tayyip Erdoğan University, Rize, TURKEY